对口服司美格鲁肽 25 毫克早期反应者：OASIS 4 试验的事后分析.pdf

1、Early responders to oral semaglutide 25 mg:A post hoc analysis of the OASIS 4 trialW.Timothy Garvey1,Oscar Birkhan2,Naveen Rathor2,Chaithra Shaji3,Domenica Rubino4PO4.274https:/ QR code or visit the website below for:Poster plus slidesAim This secondary analysis of the OASIS 4 trial(NCT05564117)inve

2、stigated body weight reductions ofearlyresponders(definedasparticipantswhoachieved10%,7.5%and5%bodyweightreductionby week 16)and responders.Additionally,the median time to achieve sustained bodyweightreductionthresholdsof5%,10%,15%and20%,andtheproportionofparticipantswhomaintained these reductions w

3、ere assessed.Introduction In the OASIS 4 trial,after 64 weeks,participants who received once-daily oral semaglutide 25 mg had a meanbodyweightchangeof13.6%,comparedwith2.2%withplacebo.1 To date,there are limited data characterising the early response to oral semaglutide in terms of the degree and ra

4、te of body weight reduction.This secondary analysis investigated body weight change of early responders,in addition to the time to and proportion of participants maintaining categorical body weight reductions.Methods In OASIS 4,participants with a body mass index(BMI)of30kg/m2(or27kg/m2with1obesity-

5、relatedcomplication)without diabetes were randomised 2:1 to receive once-daily oral semaglutide 25 mg or placebo,plus lifestyle intervention,for 64 weeks(Figure 1).This secondary analysis investigated:Body weight change of early responders(categorised asparticipantswhoachieved10%,7.5%and5%body weigh

6、t reduction by week 16,encompassing 4 weeks of maximal dosing)and responders who didnotmeetthesethresholds(10%,7.5%and5%body weight reduction)by week 16.Early responders were not presented for the placebo group because of low participant numbers within each subgroup.The median time to achieve sustai